UK Markets close in 1 hr 53 mins

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.86+0.19 (+1.39%)
As of 09:30AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close13.67
Open13.70
Bid13.14 x 1300
Ask14.21 x 800
Day's range13.75 - 13.86
52-week range12.03 - 33.09
Volume1,127
Avg. volume339,463
Market cap591.428M
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:50 p.m. ET. The webcast of the presentation will be contemporaneous

  • Globe Newswire

    Merus Announces Financial Results for the Third Quarter and Provides Business Update

    – Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics– Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potential BLA filing– Clinical update of petosemtamab planned for first half of 2023 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company

  • Globe Newswire

    Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

    - MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels​ - Initial recommended phase 2 dose 1500 mg every two weeks; expansion cohorts enrolling - Investor call to discuss a MCLA-129 program update on October 26 at 13:30 CET/7:30am ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we